B. Riley set a $3.00 price target on Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) in a research note issued to investors on Wednesday morning. The firm currently has a buy rating on the biotechnology company’s stock.
Several other equities research analysts have also commented on ATNM. Zacks Investment Research lowered shares of Actinium Pharmaceuticals from a buy rating to a hold rating in a research report on Monday, January 8th. Maxim Group set a $3.00 target price on shares of Actinium Pharmaceuticals and gave the stock a buy rating in a research report on Tuesday, December 12th. Five analysts have rated the stock with a buy rating, The company presently has a consensus rating of Buy and a consensus price target of $3.75.
Shares of Actinium Pharmaceuticals (NYSEAMERICAN ATNM) opened at $0.41 on Wednesday. The company has a market cap of $32.44, a price-to-earnings ratio of -0.87 and a beta of 40.64. Actinium Pharmaceuticals has a 1 year low of $0.40 and a 1 year high of $1.68.
An institutional investor recently raised its position in Actinium Pharmaceuticals stock. D.A. Davidson & CO. increased its holdings in Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) by 227.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 157,000 shares of the biotechnology company’s stock after buying an additional 109,000 shares during the period. D.A. Davidson & CO. owned about 0.20% of Actinium Pharmaceuticals worth $104,000 as of its most recent SEC filing.
ILLEGAL ACTIVITY NOTICE: This report was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://ledgergazette.com/2018/03/15/b-riley-reiterates-3-00-price-target-for-actinium-pharmaceuticals-atnm.html.
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.